Novo’s obesity superstar Wegovy wins FDA nod to cut cardio risks in key label expansion

Fierce Pharma March 8, 2024
Zoey Becker

Novo Nordisk’s fast-growing weight loss med Wegovy just added a new cardiovascular FDA approval to its label, likely enabling the med’s superstar status to reach new levels.

The med is now the first weight loss treatment to score an FDA nod to reduce the risk of cardiovascular death, heart attack and stroke in adult patients with cardiovascular disease who have obesity or are overweight.

It’s a “major advance for public health” in a population with an elevated risk of severe cardiovascular outcomes, the FDA Center for Drug Evaluation and Research’s head of diabetes, lipid disorders and obesity, John Sharretts, M.D., said in the agency’s release.

The FDA based the approval on Novo’s SELECT cardiovascular outcomes trial, which tested Wegovy over...

Today's Sponsors

Today's Sponsor